TSI Test

Most thyroid tests tell you how much hormone your thyroid is making right now. This test answers a different question: is your immune system the reason why? TSI (thyroid stimulating immunoglobulin) is an antibody your body should not be making. When it shows up, it means your immune system has turned against a specific receptor on your thyroid cells, effectively jamming the "on" switch and forcing your thyroid to produce excess hormone. That pattern has a name: Graves' disease, the most common cause of an overactive thyroid.

A standard thyroid panel can tell you that your thyroid is overactive, but it cannot tell you why. TSI closes that gap. If the antibody is present, the diagnosis is nearly certain. If it is absent, your doctor needs to look elsewhere for the cause. For anyone already being treated for Graves' disease, tracking TSI over time can reveal whether your immune system is calming down or gearing up for a relapse.

What TSI Is and How It Works

TSI is an IgG antibody, a type of immune protein normally designed to fight infections. In Graves' disease, certain immune cells (B lymphocytes) start producing antibodies that lock onto a structure on the surface of thyroid cells called the TSH receptor. This is the same receptor that your pituitary gland uses to tell the thyroid how much hormone to make. When TSI binds to it, the receptor cannot tell the difference between the real signal and the impostor. It activates the same internal chain reaction, triggering the thyroid to grow larger and produce more thyroid hormone than your body needs.

The result is hyperthyroidism: a racing heart, weight loss, tremor, heat intolerance, and anxiety, among other symptoms. In some people, the same antibodies also target tissues behind the eyes, causing swelling and bulging (Graves' eye disease). The higher the TSI level, the more aggressively the immune system is stimulating the thyroid, and the more likely these complications become.

Graves' Disease Diagnosis

TSI is the single most accurate blood test for confirming Graves' disease as the cause of hyperthyroidism. A 2025 meta-analysis found TSI has a pooled sensitivity of 93.3% and specificity of 96.1%, meaning it correctly identifies the vast majority of people with Graves' disease and very rarely produces a false alarm. Modern bioassays report even higher numbers, reaching 96 to 98% sensitivity and 99% specificity in some studies.

This matters because hyperthyroidism has several possible causes, and treatment depends on which one you have. Graves' disease (immune-driven) is treated very differently from a thyroid nodule that is autonomously producing hormone, or from thyroiditis (inflammation causing a temporary hormone leak). A single TSI test can often settle the question and spare you a nuclear medicine scan.

How TSI Differs from TRAb

You may see another test called TRAb (thyrotropin receptor antibody). Both tests look at antibodies targeting the TSH receptor, but they measure different things. TRAb binding assays detect all antibodies that attach to the receptor, whether they stimulate the thyroid, block it, or do nothing at all. TSI assays specifically measure antibodies that activate the receptor and drive hormone production. This distinction matters in rare cases where blocking antibodies are present, which can cause a positive TRAb but would actually slow thyroid function rather than speed it up.

In head-to-head comparisons, the two tests agree about 88 to 93% of the time. When they disagree, TSI tends to align better with the final clinical diagnosis. Analysis of over 189,000 patient encounters found that ordering both tests together, which happens in 14 to 17% of cases, increases costs by 31 to 325% without adding meaningful diagnostic value. One test is enough for most situations.

Predicting Relapse After Treatment

Beyond initial diagnosis, TSI is valuable for predicting what happens after you stop treatment. Most people with Graves' disease start with antithyroid medication (typically methimazole) for 12 to 18 months. The hard question is whether the disease will come back when the medication stops. TSI helps answer that.

People who are TSI-negative at the time they stop medication have significantly lower relapse rates compared to those who remain positive. One study found that a TSI level of 1.31 IU/L or higher during low-dose maintenance therapy predicted relapse with 63.6% sensitivity and 78.8% specificity. Higher TSI at diagnosis also correlates with longer treatment duration and greater likelihood of relapse. Persistent TSI positivity after five years of treatment is a particularly strong warning sign.

Pregnancy and Neonatal Risk

TSI antibodies can cross the placenta. In pregnant women with current or past Graves' disease, elevated maternal TSI (more than 3 to 5 times the upper limit of normal) increases the risk that the baby will develop temporary neonatal Graves' disease. Guidelines from the American Thyroid Association and ACOG recommend measuring TSI during pregnancy in women with a history of Graves' disease to guide fetal monitoring decisions.

Graves' Eye Disease

TSI levels also correlate with the severity of Graves' ophthalmopathy, the eye swelling, redness, and protrusion that can accompany Graves' disease. Higher antibody levels tend to predict more severe eye involvement. While the relationship is not perfect, tracking TSI in someone with eye symptoms gives an additional signal about how active the underlying immune process is.

Reference Ranges

TSI is not a biomarker with "optimal" and "borderline" zones the way cholesterol or blood sugar are. It is essentially a yes-or-no test: the antibody is either present or it is not. When present, higher levels generally indicate more aggressive disease. The exact cutoff for a positive result depends on which assay your lab uses.

These thresholds are assay-specific. A result from one platform cannot be directly compared to a result from another. If you are tracking TSI over time, use the same lab and the same assay each time. A result below your lab's cutoff does not guarantee the absence of Graves' disease, as about 21% of confirmed cases can test negative, particularly in mild, subclinical, or longstanding disease.

When Results Can Be Misleading

TSI is less prone to everyday confounders than most blood tests. Unlike thyroid hormones, which shift with acute illness, stress, fasting, and time of day, TSI reflects the activity of your immune system against a specific target and does not fluctuate with meals, exercise, or short-term stress. That said, a few things can produce misleading results.

• Biotin supplements: High-dose biotin (above 100 mg per day), sometimes taken for hair or nail health, can cause false-positive results in assays that use biotin-streptavidin chemistry. If you take biotin, stop it for 2 to 7 days before your blood draw.
• Subclinical or mild disease: TSI can be falsely negative in people with very mild hyperthyroidism, subclinical disease (suppressed TSH but normal hormone levels), or Graves' disease that has been present for a long time without treatment. The absence of goiter or eye symptoms also increases the chance of a false negative.
• Blocking antibodies: In rare cases, a person may have both stimulating and blocking antibodies targeting the TSH receptor. TRAb assays may be positive from either type, while TSI assays specifically detect the stimulating variety. The clinical picture can shift over time as the balance between stimulating and blocking antibodies changes.

Tracking Your Trend

A single TSI reading is most useful at the moment of diagnosis, when it answers the question "is this Graves' disease?" But the real power of this test comes from serial measurements over the course of treatment. TSI levels typically fall during antithyroid drug therapy. The rate and completeness of that decline tells you whether the immune process is quieting down.

The standard approach is to measure TSI at diagnosis, then again before considering whether to stop medication (typically after 12 to 18 months of treatment). If TSI has become negative, remission is more likely. If it remains elevated, relapse is more probable, and your treatment plan may need to change. After radioactive iodine or thyroidectomy, TSI can be tracked to confirm that antibody levels are falling, which has implications for eye disease risk.

Always use the same lab and assay for serial measurements. Different platforms have different cutoffs and sensitivities, and switching labs mid-course can make it impossible to compare your results meaningfully.